Mapping/Ablation

In September 2024, the first sham-controlled AF ablation trial was published simultaneous with presentation of the study findings at the European Society of Cardiology (ESC) Congress 2024.

EP Lab Digest talks with Benjamin A Steinberg, MD, MHS, FHRS, about findings and implications of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry.

Evangelos A Diamantakos, DO, FHRS, FACC, FACOI, discusses how to identify patients for leadless pacing and offers implantation and troubleshooting techniques.

Historically, more resources, attention, and personnel are dedicated to the cardiac operating rooms, cardiac intensive care units, and catheterization laboratories than to the EP laboratories. There are many reasons why.

EP Lab Digest speaks with Ahmad Masri, MD, MS, about contemporary management of hypertrophic cardiomyopathy, including recent advances, pharmacologic treatment options, new guidelines, and future directions.

It is unrealistic to expect zero complications from an invasive procedure. It is also important to learn that trying to lower the rate of serious adverse events from 2% to 1% in the EP lab can require much more than twice the effort.

Gene therapy targeting the underlying desmosomal mutation and approaches to prevent myocardial fibrosis independent of the specific genetic defect by increasing cardiac levels of FGF21 may be on the horizon for patients with ARVC.

Sarah Vanderhoff, MSN, RN, and Andrew Feltgen, RT(R), describe the development, structure, and outcomes of Scripps’ Interventional Cardiology Rad Tech Transition Program.

It is surprising that in the latest atrial fibrillation guideline, not a single antiarrhythmic drug is considered to have a class I indication.

As computer science has enjoyed groundbreaking advances that have transformed other sectors of society, the idea of its application in medicine has generated excitement over its potential to fill knowledge gaps.